Fecal Transplant for Clostridioides difficile Infection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational effort takes place within the Center for Fecal Microbiota Transplantation at Aarhus University Hospital. Patients with confirmed Clostridioides difficile infection are assessed, treated, and monitored as part of an integrated care project across AUH and affiliated hospitals. The study focuses on real-world use of fecal microbiota transplantation to understand safety, feasibility, and potential outcomes in routine clinical practice. No randomization or experimental design is described beyond observation of standard FMT procedures. The lead institution is Aarhus University, with care delivered at Aarhus University Hospital in Aarhus N and partner sites.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* age 18 or higher
* documented Clostridioides difficile infection

Exclusion Criteria:

* none

Where it's running

• Aarhus University Hospital
  Aarhus N, Denmark Recruiting

Study contacts

• Study coordinator: Christian L Hvas, MD PhD
• Email: christian.hvas@auh.rm.dk
• Phone: +4528351839

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using alanyl-glutamine to treat C. difficile infections

  This study is testing if taking alanyl-glutamine can help people with C. difficile infections recover better and prevent the infection from coming back.

  Recruiting at 2 sites Phase 2 University of Virginia · Charlottesville, Virginia and 1 other locations · NCT04305769

• Orally ingested yeast designed to express a tetra-specific anti-toxin for Clostridioides difficile safety study

  This first-in-human trial tests a yeast-based medicine (FZ002) to see if it is safe and tolerable for adults with no active infection, using a placebo for comparison.

  Recruiting Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · Knoxville, Tennessee · NCT07649096

• Diet and counseling to see how meals affect gut health after CDI

  We’re testing whether different meal plans and health counseling can influence the gut microbiome and reduce chances of CDI coming back in adults who are being treated for CDI.

  Recruiting University of Michigan · Ann Arbor, Michigan · NCT07613645

• Lyophilized fecal microbiota transplant for adults with active ulcerative colitis

  This trial will test whether a dried (lyophilized) fecal microbiota transplant helps adults with active ulcerative colitis when added to their current treatment or started alongside a new advanced medication.

  Recruiting Phase 1 University of Alberta · Calgary, Alberta and 1 other locations · NCT07401680

• How antibiotics versus fecal transplants affect recovery from C. difficile infection

  This project will see how antibiotics and fecal microbiota transplant (FMT) affect adults with C. difficile infection by tracking recovery and biological changes over time.

  Recruiting Umeå University · Umeå · NCT07374094

• Preventing recurrent C. difficile infection with the AZD5148 antibody

  This will try a single dose of the antibody AZD5148 versus placebo to see if it prevents repeat C. difficile infections in adults being treated for a current infection.

  Recruiting at 95 sites Phase 2 AstraZeneca · Phoenix, Arizona and 116 other locations · NCT07285213

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.